<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069030</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 044</org_study_id>
    <secondary_id>5K08AI051223-03</secondary_id>
    <secondary_id>10120</secondary_id>
    <nct_id>NCT00069030</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will test the safety of and immune system response to a new HIV vaccine. The&#xD;
      vaccine in this study is made from HIV DNA produced in a laboratory. Only part of the virus's&#xD;
      DNA is used in the vaccine and the vaccine itself cannot cause HIV infection or AIDS. In&#xD;
      addition to HIV DNA, the vaccine contains interleukin-2 (IL-2) DNA fused to a portion of&#xD;
      immunoglobulin (Ig) DNA. IL-2 is a chemical that stimulates the immune system and may improve&#xD;
      response to the vaccine.&#xD;
&#xD;
      Study hypothesis: The IL-2/Ig plasmid will be very well tolerated in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 90% of the 40 million people infected with HIV live in developing countries and have&#xD;
      little or no access to antiretroviral medications. The worldwide HIV/AIDS epidemic will only&#xD;
      be controlled through development of a safe and effective vaccine that will prevent HIV&#xD;
      infection. DNA vaccines are inexpensive to construct, readily produced in large quantities,&#xD;
      and stable for long periods of time. The DNA vaccine in this study, VRC-HIVDNA009-00-VP&#xD;
      (Gag-Pol-Nef-multiclade Env), uses multiple gene products to increase the breadth of the&#xD;
      immune response across different HIV subtypes. The DNA plasmids in VRC-HIVDNA009-00-VP code&#xD;
      for proteins from HIV subtypes A, B, and C, which together represent 90% of new HIV&#xD;
      infections in the world.&#xD;
&#xD;
      The study vaccine is administered with an adjuvant. The adjuvant is a DNA plasmid encoding&#xD;
      interleukin 2 (IL-2) fused to the Fc portion of IgG for enhanced stability. This IL-2/Ig&#xD;
      adjuvant may augment the immune system's response to the vaccine.&#xD;
&#xD;
      Participants in this study will be randomly assigned to receive either the vaccine and&#xD;
      adjuvant, the vaccine and placebo, the adjuvant and placebo, or placebo alone. All injections&#xD;
      will be administered by needle-free injection in the upper arm. Participants will receive&#xD;
      four does of vaccine: one at their first study visit and then at Months 1, 2, and 6.&#xD;
      Participants will have a follow-up visit 2 days after each injection. Some participants may&#xD;
      receive another injection at this follow-up visit. All study participants will be followed&#xD;
      for 18 months and will have 16 to 20 study visits. Study visits will last 1/2 to 2 hours and&#xD;
      will include blood and urine tests and a physical exam. Participants will also have six HIV&#xD;
      tests over the course of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical observation and monitoring of hematological, chemical, and immunologic parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>local and systemic adverse reactions after each injection and for 12 months after last injection</measure>
  </primary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Acceptable methods of contraception for females of reproductive potential&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is&#xD;
             positive&#xD;
&#xD;
          -  Normal thyroid stimulating hormone (TSH) level&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  HIV vaccines or placebos in prior HIV vaccine trial&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to first study vaccine&#xD;
             administration&#xD;
&#xD;
          -  Blood products within 120 days prior to first study vaccine administration&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to first study vaccine administration&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to first study vaccine administration&#xD;
&#xD;
          -  Investigational research agents within 30 days prior to first study vaccine&#xD;
             administration&#xD;
&#xD;
          -  Subunit or killed vaccines within 14 days prior to first study vaccine administration&#xD;
&#xD;
          -  Current tuberculosis prophylaxis or therapy&#xD;
&#xD;
          -  Clinical depression with pharmacological treatment within the past 2 years&#xD;
&#xD;
          -  Active syphilis&#xD;
&#xD;
          -  Serious adverse reaction to vaccines. A person who had an adverse reaction to&#xD;
             pertussis vaccine as a child is not excluded.&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Unstable asthma&#xD;
&#xD;
          -  Type 1 or Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Thyroid disease requiring treatment&#xD;
&#xD;
          -  Serious angioedema within the past 3 years&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Malignancy unless it has been surgically removed and, in the opinion of the&#xD;
             investigator, is not likely to recur during the study period&#xD;
&#xD;
          -  Seizure disorder requiring medication within the past 3 years&#xD;
&#xD;
          -  Asplenia&#xD;
&#xD;
          -  Mental illness that would interfere with compliance with the protocol&#xD;
&#xD;
          -  Other conditions that, in the judgement of the investigator, would interfere with the&#xD;
             study&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Dolin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard Medical School (HMS and HSDM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Project Brave HIV Vaccine CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health Clinical Research Site (FCHCRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Blood Ctr./Bronx CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Blood Ctr./Union Square CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Prevention &amp; Treatment CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital's HVTU</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information on HIV preventive vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1487</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000 Oct 20;290(5491):486-92.</citation>
    <PMID>11039923</PMID>
  </reference>
  <reference>
    <citation>Barouch DH, Santra S, Steenbeke TD, Zheng XX, Perry HC, Davies ME, Freed DC, Craiu A, Strom TB, Shiver JW, Letvin NL. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998 Aug 15;161(4):1875-82.</citation>
    <PMID>9712056</PMID>
  </reference>
  <reference>
    <citation>Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol. 2001 Jul;75(13):5721-9. Review.</citation>
    <PMID>11390574</PMID>
  </reference>
  <reference>
    <citation>Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. AIDS. 2001 Apr 13;15(6):W1-W25.</citation>
    <PMID>11371709</PMID>
  </reference>
  <reference>
    <citation>Walker LG, Walker MB, Heys SD, Lolley J, Wesnes K, Eremin O. The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psychooncology. 1997 Dec;6(4):290-301.</citation>
    <PMID>9451748</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 12, 2003</study_first_submitted>
  <study_first_submitted_qc>September 15, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2003</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <keyword>HIV-1</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>Vaccines, DNA</keyword>
  <keyword>Dose-Response Relationship, Immunologic</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Plasmids</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>Interleukin</keyword>
  <keyword>IL2</keyword>
  <keyword>Ig</keyword>
  <keyword>IL@/Ig</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

